Topic

Articles

Samsung Biologics and Kineta have entered into a strategic partnership for drug product manufacturing services and to support an IND filing of a novel antibody therapeutic. 

Samsung Biologics Partners with Kineta for Anti-VISTA Antibody Immunotherapy

BioNTech will acquire a TCR cell therapy R&D platform as well as a manufacturing facility in Gaithersburg, Md., from Kite, a Gilead company. 

BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Manufacturing Facility

Nkarta will establish a new combined scalable NK cell therapy manufacturing facility and corporate headquarters in South San Francisco, Calif.

Nkarta Establishes New NK Cell Therapy Manufacturing Facility and Headquarters

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

Pall has secured a manufacturing contract with Exothera for the suspension-based manufacture of gene therapies and viral vector-based vaccines.

Pall Enters Multi-Million Dollar Contract with Exothera for Viral Vector Manufacturing

The US federal government awarded new funding to the National Institute for Innovation in Manufacturing Biopharmaceuticals, including funding under the American Rescue Plan that will be used to advance vaccine manufacturing. 

NIIMBL Receives Federal Funding for Biopharmaceutical Manufacturing Projects

Feliza Mirasol is the science editor for 

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.

Complex Biomolecules Require Analytical Evolution

Thomas A. Little, PhD, is president, Thomas A. Little Consulting and BioAssay Sciences, 12401 North Wildflower Lane, Highland, Utah 84003, USA, drlittle@dr-tom.com.

Developing analytical methods and bioassays is necessary from early on in the drug development life cycle.

Best Practices for Analytical Method Validation: Study Design, Analysis, and Acceptance Criteria

A new report by Radnor Capital Partners and commissioned by the BIA has shown that international investors are being drawn toward the biotech sector of the UK.

UK Biotech Attracts International Investment, According to New Analysis

Eli Lilly and Company has announced its acquisition of biotech firm Protomer Technologies, giving it a protein-engineering platform for next-generation protein therapeutics.

BioBusiness